Persistence of Metabolomic Changes in Patients during Post-COVID Phase: A Prospective, Observational Study.
COVID-19
NMR spectroscopy
SARS-CoV-2
metabolome
post-COVID
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
13 Jul 2022
13 Jul 2022
Historique:
received:
13
06
2022
revised:
07
07
2022
accepted:
10
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Several relatively recently published studies have shown changes in plasma metabolites in various viral diseases such as Zika, Dengue, RSV or SARS-CoV-1. The aim of this study was to analyze the metabolome profile of patients during acute COVID-19 approximately one month after the acute infection and to compare these results with healthy (SARS-CoV-2-negative) controls. The metabolome analysis was performed by NMR spectroscopy from the peripheral blood of patients and controls. The blood samples were collected on 3 different occasions (at admission, during hospitalization and on control visit after discharge from the hospital). When comparing sample groups (based on the date of acquisition) to controls, there is an indicative shift in metabolomics features based on the time passed after the first sample was taken towards controls. Based on the random forest algorithm, there is a strong discriminatory predictive value between controls and different sample groups (AUC equals 1 for controls versus samples taken at admission, Mathew correlation coefficient equals 1). Significant metabolomic changes persist in patients more than a month after acute SARS-CoV-2 infection. The random forest algorithm shows very strong discrimination (almost ideal) when comparing metabolite levels of patients in two various stages of disease and during the recovery period compared to SARS-CoV-2-negative controls.
Identifiants
pubmed: 35888766
pii: metabo12070641
doi: 10.3390/metabo12070641
pmc: PMC9321209
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Regional Development Fund
ID : ITMS: 313011ASX4
Organisme : European Regional Development Fund
ID : ITMS: 313011AUA4
Références
BioData Min. 2021 Feb 4;14(1):13
pubmed: 33541410
Signal Transduct Target Ther. 2021 Dec 16;6(1):427
pubmed: 34916489
World J Diabetes. 2015 Jul 25;6(8):1073-81
pubmed: 26240704
Eur J Pharmacol. 2005 Apr 18;513(1-2):145-50
pubmed: 15878720
J Cell Mol Med. 2018 Oct;22(10):4948-4962
pubmed: 30063118
Eur Respir J. 2022 Feb 24;59(2):
pubmed: 34289974
Metabolism. 2021 May;118:154739
pubmed: 33662365
EMBO J. 2022 Jun 14;41(12):e108306
pubmed: 35506364
Amino Acids. 2011 Apr;40(4):1077-90
pubmed: 20839016
Adv Exp Med Biol. 2015;872:99-126
pubmed: 26215992
Int J Mol Sci. 2020 Nov 16;21(22):
pubmed: 33207699
Anal Bioanal Chem. 2018 Sep;410(23):5981-5992
pubmed: 29959482
Anal Chem. 2015 Jan 6;87(1):706-15
pubmed: 25485990
J Inflamm Res. 2021 Sep 07;14:4485-4501
pubmed: 34522117
Nutrients. 2016 Jul 01;8(7):
pubmed: 27376324
Clin Infect Dis. 2021 Dec 16;73(12):2228-2239
pubmed: 33596592
Viruses. 2019 Mar 06;11(3):
pubmed: 30845653
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Food Chem Toxicol. 2008 May;46(5):1503-9
pubmed: 18222027
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Diabet Med. 2021 Jan;38(1):e14378
pubmed: 32740972
Metabolomics. 2013 Apr;9(2):280-299
pubmed: 23543913
J Neurosurg Anesthesiol. 2004 Apr;16(2):122-5
pubmed: 15021280
Mediators Inflamm. 2018 Aug 27;2018:9524075
pubmed: 30224900
Natl Sci Rev. 2020 Jul;7(7):1157-1168
pubmed: 34676128
Front Cardiovasc Med. 2021 May 20;8:644095
pubmed: 34124187
Nutrients. 2020 Mar 22;12(3):
pubmed: 32235743
Sci Rep. 2017 Aug 22;7(1):9110
pubmed: 28831119
Front Genet. 2021 Jul 23;12:721556
pubmed: 34367265
Sci Rep. 2022 Jan 31;12(1):1650
pubmed: 35102215
J Nutr. 2005 Jun;135(6 Suppl):1539S-46S
pubmed: 15930466
Mol Metab. 2020 Sep;39:101044
pubmed: 32585364
Pediatr Allergy Immunol. 2020 Oct;31(7):755-766
pubmed: 32460384
Cell Death Dis. 2021 Mar 11;12(3):258
pubmed: 33707411